Tesofensine
Tesofensine: an experimental weight-loss pill never approved by FDA, its Mexico application, phase 2 trial results, side effects and sport ban.
Investigational, not FDA-approved · Evidence grade B · Reviewed
Not approved by the FDA for human use. Not for human consumption. This page describes Tesofensine only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer
- Not approvedWeight managementIn trials; not FDA-approved
Tesofensine (NS2330, also tested with metoprolol as Tesomet). Triple monoamine reuptake inhibitor.
BInvestigational, not FDA-approved. Evidence grade B: human trials, narrow or pending approval.
What is Tesofensine?
Tesofensine is an experimental pill that blocks the reuptake of serotonin, noradrenaline and dopamine, brain chemicals that affect appetite. It was first studied for Parkinson's and Alzheimer's disease and is now developed for obesity.
Is Tesofensine FDA-approved?
FDA has never approved tesofensine. Its Latin American partner has applied for approval in Mexico; as of November 2026 we could not confirm an approval there. Products sold online in the US as tesofensine are unapproved drugs.
What does the evidence show for Tesofensine?
A 24-week phase 2 trial in 203 adults with obesity (Lancet, 2008) found more weight loss than placebo; in 2013 the journal published an expression of concern about the paper. Later phase 3 results from Mexico have been reported by the sponsor, but we could not check them in a peer-reviewed source.
What are the known risks of Tesofensine?
In the phase 2 trial the most common side effects were dry mouth, nausea, constipation, diarrhea and insomnia, and heart rate rose. Long-term heart safety is unknown. Products sold online are unregulated, so their content and purity are unknown. WADA prohibits tesofensine in competition as a specified stimulant (S6.B).
How is Tesofensine measured?
A tablet, so there is nothing to draw or calculate. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: Astrup et al., tesofensine in obese patients, phase 2 trial (2008); Lancet expression of concern (2013); WADA: 2026 Prohibited List. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.